Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics - sprookjes - yvandenbroek - TriplyDB

Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics

Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics

http://www.wikidata.org/entity/Q24651239

about

Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer Using germline genomics to individualize pediatric cancer treatments Systemic therapies for pancreatic cancer--the role of pharmacogenetics Pharmacogenomics of chemotherapeutic susceptibility and toxicity UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy Pharmacogenetics and Predictive Testing of Drug Hypersensitivity Reactions Irinotecan pharmacogenomics Multidrug resistance-associated protein 1 (MRP1/ABCC1) polymorphism: from discovery to clinical application Flavopiridol pharmacogenetics: clinical and functional evidence for the role of SLCO1B1/OATP1B1 in flavopiridol disposition Strain- and sex-dependent circadian changes in abcc2 transporter expression: implications for irinotecan chronotolerance in mouse ileum The role of intestinal microbiota in development of irinotecan toxicity and in toxicity reduction through dietary fibres in rats Effect of ABCB1 and ABCC3 polymorphisms on osteosarcoma survival after chemotherapy: a pharmacogenetic study Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management.Effects of methimazole on the elimination of irinotecan.Differences in UGT1A1, UGT1A7, and UGT1A9 polymorphisms between Uzbek and Japanese populations Effects of mannose-binding lectin polymorphisms on irinotecan-induced febrile neutropenia.Virtual Clinical Studies to Examine the Probability Distribution of the AUC at Target Tissues Using Physiologically-Based Pharmacokinetic Modeling: Application to Analyses of the Effect of Genetic Polymorphism of Enzymes and Transporters on Irinotec Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years Association of carboxylesterase 1A genotypes with irinotecan pharmacokinetics in Japanese cancer patients Urinary coproporphyrin I/(I + III) ratio as a surrogate for MRP2 or other transporter activities involved in methotrexate clearance.The pharmacogenomics of membrane transporters project: research at the interface of genomics and transporter pharmacology.A novel system for predicting the toxicity of irinotecan based on statistical pattern recognition with UGT1A genotypes.Pharmacogenetics of irinotecan: An ethnicity-based prediction of irinotecan adverse events.Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer.Metabolic pathways of the camptothecin analog AR-67 Repositioning of Tyrosine Kinase Inhibitors as Antagonists of ATP-Binding Cassette Transporters in Anticancer Drug Resistance Clinical implications of UGT1A1*28 genotype testing in colorectal cancer patients.Estimation of feasible solution space using Cluster Newton Method: application to pharmacokinetic analysis of irinotecan with physiologically-based pharmacokinetic models.Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors.The association of transporter genes polymorphisms and lung cancer chemotherapy response An internally and externally validated nomogram for predicting the risk of irinotecan-induced severe neutropenia in advanced colorectal cancer patients Methylenetetrahydrofolate reductase genetic polymorphisms and toxicity to 5-FU-based chemoradiation in rectal cancer.OATP1B1 and tumour OATP1B3 modulate exposure, toxicity, and survival after irinotecan-based chemotherapy UGT1A1 is a major locus influencing bilirubin levels in African Americans.Relationship between UGT1A1*6/*28 polymorphisms and severe toxicities in Chinese patients with pancreatic or biliary tract cancer treated with irinotecan-containing regimens Effect of ABCC2 (MRP2) transport function on erythromycin metabolism Contribution of tumoral and host solute carriers to clinical drug response.Whole-genome studies identify solute carrier transporters in cellular susceptibility to paclitaxel.Efflux transporter variants as predictors of drug toxicity in lung cancer patients: systematic review and meta-analysis.Chemotherapy-induced neutropenia during adjuvant treatment for cervical cancer patients: development and validation of a prediction model.

P2860

Q26775949-A4783241-C2C0-4075-8F69-D4FF29964A9D Q27003261-F85FC350-B89E-424A-BA5E-08C777F57D67 Q27021716-9D97F420-9751-48AB-AB31-B9B41E7E7BD5 Q27025558-B08C8298-A377-4425-8208-6D02D0E15C62 Q27851574-C442C874-F87F-403C-9D2C-EB53D3B4BE20 Q28066096-30AF961A-8C66-47AF-8A73-A8B863BF67CD Q28287024-58BD9AB5-2352-4C5E-803D-A48F0515B7D5 Q28468693-51768FF3-1928-4CFC-8317-81FEBD65646D Q28475976-8108F563-CDE1-47C2-A7C3-8D8A1EB8E0A5 Q28478419-1F3FCD47-0B30-4C9A-9125-B12CB9C57B51 Q28538671-BD615EEC-A492-4966-A262-B13EA894F924 Q28744127-970DE7D1-1FC9-4037-8A73-98146BFD9547 Q30318822-955F93E1-0478-4E6A-B4E6-7A20930DAFAD Q33647853-414E5B09-C865-47E2-8129-813F0B27AF76 Q33651706-8945678F-135B-41F9-AFBA-FA15B9F3CCA1 Q33712655-369B1355-C7D1-479A-A357-F495B1A7A5D2 Q33875931-2F1EF7B1-CF23-4155-A941-FD42E7614341 Q34008793-8F803BAA-FB2B-4DE6-BC62-AD5756DE0366 Q34026252-D5F439BA-7CEA-4841-AE22-D165B4A5750F Q34065294-C3738B66-4B85-4396-8951-63ABED7BAA28 Q34071782-147395DD-AB8E-4085-B7B1-4CEA85945DD1 Q34120416-492FCCCE-5F72-4027-969A-718A0DDE862F Q34391234-88C7F4C3-3430-4863-9202-4772F6AD2088 Q34565071-8D280061-ED47-4A51-87CB-2AD4B96331BE Q34715481-4A45566D-30B8-4061-834A-E25167B9E9D7 Q34774854-2FB0DF60-489A-4440-AB1B-02DEBD17B26A Q35050772-BD4015B9-EC07-4A61-A031-520694DA3F8A Q35099010-7C5C691A-4717-4856-86BF-3D417BB27F52 Q35100986-BFA523AC-23A5-4CCF-884C-D2DFCFEA0877 Q35124361-9FD05FB8-2B52-4E12-A19B-990EA4B670CF Q35603648-6FF0E231-A429-4308-80D8-E72206E0439A Q35623320-C2C83652-3434-437B-8C4E-F8804A5658C5 Q35678729-0FBC10FC-EAA7-4313-97AA-4D097195F2C1 Q35837634-0BF7EDD3-3216-4C4E-A2F0-97297CC2201E Q35887458-6D877B4D-E13A-4FFD-B4CB-83A6C3564926 Q35902300-50AD085B-41F3-4337-AD2F-165213234347 Q35946876-630DE92D-0AAB-4269-AA4B-D6392110BB21 Q36035404-AE922991-94CD-4517-B2CD-213F9820D2AA Q36043023-BC1DC2E0-677A-4ACD-ACF4-BFDB5DC65FF6 Q36046284-1BD26B35-07A8-4CC5-809C-4984E4D30E8A

P2860

Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics

http://www.wikidata.org/entity/Q24651239

description

2009 nî lūn-bûn

@nan

2009 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics

@ast

Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics

@en

Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics

@nl

type

label

Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics

@ast

Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics

@en

Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics

@nl

prefLabel

Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics

@ast

Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics

@en

Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics

@nl

P1433

Q24651239-199FC48A-B575-4CF8-9201-D5ED6DCCF029

P1476

Q24651239-25A67F8C-C0DE-45CB-8294-872402565469

P2093

Q24651239-0A6DCFC6-F8BD-4732-B8D3-9EBF3069BA94

Q24651239-1D2E5268-692E-4A46-982E-44E1076BA771

Q24651239-2C7A2F4E-81E2-402B-8AD5-77BCD189D5A1

Q24651239-2D55BBA1-D6E1-400D-B885-55C6E4A7719E

Q24651239-622CEF5F-6693-45E9-A98C-249311DD6BE0

Q24651239-6FDD54D0-C8CA-4EB6-AA6D-538A16822E38

Q24651239-988C1C27-4AD6-41C8-8238-B431233BFCE0

Q24651239-9DB706BD-39E5-4F94-BB75-49A808326AD1

Q24651239-FAB89307-BCC4-42FD-9FA5-377C35431CA0

P2860

Q24651239-023D7FEC-9A5C-4920-B345-4DE8E0623353

Q24651239-11E10D0B-D48C-4AD6-AF2E-C71A7D6B9282

Q24651239-3EB3A19F-556C-46B3-8EB1-D3EE7B9306F2

Q24651239-3F74D664-A973-4351-A302-74C78A0376DA

Q24651239-4588014F-8AA9-41B8-A2BE-AC02AE100ACD

Q24651239-4BCA8B15-233B-4667-9EE7-AAED2547EF7D

Q24651239-4D003F8D-7D2C-4AB8-846F-C6A2F1BCE47D

Q24651239-501E376B-2BC1-4B4E-AFF4-97951F80B497

Q24651239-5C95601E-A835-4DBD-A76F-3E6115EA3426

Q24651239-62576BAC-C0A2-4F14-96B9-2BBD4A46981D

P304

Q24651239-E2AAC42C-3209-4131-BECA-0CE34CB86A4B

P31

Q24651239-FF2CECFA-FA06-4055-93BD-8D77B9D13155

P3181

Q24651239-9C84E5BA-B2A7-4935-8D33-C5808098CE6F

P356

Q24651239-D310C5F2-9259-4ABD-BF43-C4490380FCAA

P407

Q24651239-9B615A03-29E4-4D64-BFDB-07EB6E5BE162

P433

Q24651239-E65854CA-FA58-4446-B295-0536074756BD

P478

Q24651239-0FDE2BC0-91E5-4298-AFFA-497CB509B832

P50

Q24651239-F6976013-B4F2-461C-A12D-FD82F1C79153

P577

Q24651239-0038BDC1-CBDA-42E9-8E51-785CBD6B1875

P698

Q24651239-491EBCE4-C7DC-4178-B388-913E16460C15

P921

Q24651239-3E878A48-49E4-40DA-BBF6-5AB7E3749919

P932

Q24651239-71F8EB2B-0DD1-4C63-982A-C3C8778797AA

P3181

P356

JCO.2008.20.6300

P1433

Journal of Clinical Oncology

P1476

Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics

@en

P2093

Deanna L Kroetz

http://www.w3.org/2001/XMLSchema#string

Erin Schuetz

http://www.w3.org/2001/XMLSchema#string

Federico Innocenti

http://www.w3.org/2001/XMLSchema#string

Gary L Rosner

http://www.w3.org/2001/XMLSchema#string

Jacqueline Ramírez

http://www.w3.org/2001/XMLSchema#string

M Eileen Dolan

http://www.w3.org/2001/XMLSchema#string

Mary Relling

http://www.w3.org/2001/XMLSchema#string

Peixian Chen

http://www.w3.org/2001/XMLSchema#string

Soma Das

http://www.w3.org/2001/XMLSchema#string

P2860

Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism?

Differential expression of the UGT1A locus in human liver, biliary, and gastric tissue: identification of UGT1A7 and UGT1A10 transcripts in extrahepatic tissue

Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan

Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy

Irinotecan pathway genotype analysis to predict pharmacokinetics

SLCO1B1 variants and statin-induced myopathy--a genomewide study

Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure.

Impact of body-size measures on irinotecan clearance: alternative dosing recommendations.

Flat-fixed dosing of irinotecan: influence on pharmacokinetic and pharmacodynamic variability.

Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein.

P304

2604-14

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2854059

http://www.w3.org/2001/XMLSchema#string

P356

10.1200/JCO.2008.20.6300

http://www.w3.org/2001/XMLSchema#string

P407

P433

16

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19349540

http://www.w3.org/2001/XMLSchema#string

P921

pharmacokinetics

P932

2690389

http://www.w3.org/2001/XMLSchema#string